IL6 and COVID-19: Such CRAC-related mechanism of action [24] capable of preventing systemically IL-6-driven thrombotic events [1], together with the multi-faceted capacity of metformin to ameliorate immunometabolism-related inflammation and alleviate ARDS [25–27] -which are believed to be the main risk factors for a worse outcome in the elderly with COVID-19 [28, 29]- could provide a novel mechanistic basis for the recently proposed geroprotective role of metformin against the gerophilic and gerolavic traits of SARS-CoV-2 infection [30].